Peer-reviewed veterinary case report
Epigenetic changes in dog lymphoma and treatment outlook
By Esperanza Montaner-Angoiti et al.·Published in Animals·2023·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes
- Species:
- dog
Plain-English summary
A study found that canine malignant lymphoma, a common type of cancer in dogs, often resists standard chemotherapy, especially in breeds like Labrador Retrievers and Golden Retrievers. This resistance means that new treatments are needed, and researchers are looking into epigenetic changes (which affect how genes are expressed) as potential targets for therapy. They suggest that drugs that inhibit certain enzymes involved in these changes could be promising for treating this cancer. Additionally, using microRNAs may help in diagnosing and predicting outcomes for dogs with lymphoma.
People also search for: dog lymphoma treatment · Labrador Retriever cancer prognosis · chemotherapy resistance in dogs
Abstract
Simple Summary Canine malignant lymphoma is one of the most common neoplasias in dogs. Even though breed influences the prevalence and prognosis, most cases present resistance to traditional chemotherapy. Canine breeds such as Labrador and Golden Retriever often have a worse prognosis for this reason. This high resistance to anticancer drugs makes it necessary to search for other therapies and other therapeutic targets. In this sense, the epigenetic regulators of neoplasia could be a promising object of study in the search for new research advances. Abstract Canine malignant lymphoma is a common neoplasia in dogs, and some studies have used dogs as a research model for molecular mechanisms of lymphomas in humans. In two species, chemotherapy is the treatment of choice, but the resistance to conventional anticancer drugs is frequent. The knowledge of molecular mechanisms of development and progression of neoplasia has expanded in recent years, and the underlying epigenetic mechanisms are increasingly well known. These studies open up new ways of discovering therapeutic biomarkers. Histone deacetylases and demethylase inhibitors could be a future treatment for canine lymphoma, and the use of microRNAs as diagnosis and prognosis biomarkers is getting closer. This review summarises the epigenetic mechanisms underlying canine lymphoma and their possible application as treatment and biomarkers, both prognostic and diagnostic.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/36766357